Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma
Status:
Terminated
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The primary objective is the observation and description of the preliminary efficacy of
resiquimod gel 0.06% on a single nodular basal cell carcinoma (nBCC) in a small group of
patients.